Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ)
Chongqing, CN
Fuan Pharmaceutical (Group) Co., Ltd. is a comprehensive pharmaceutical enterprise that, along with its subsidiaries, undertakes the research, development, manufacturing, and commercialization of pharmaceutical products across the People's Republic of China. Its product portfolio spans intermediate compounds, active pharmaceutical ingredients (APIs), and finished drug formulations. These formulations cater to a range of therapeutic categories, including anti-infective agents, cardiovascular medications, digestive system remedies, and various other medical products. The group was founded in 2004 and is headquartered in Chongqing, China. It adopted its current name, Fuan Pharmaceutical (Group) Co., Ltd., in August 2013, having previously been known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.79% | -2.80% | -7.51% | -14.35% | -15.86% | -13.77% | -8.17% | -8.17% | -12.98% | -34.48% | -44.31% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-27.8% Q1'26: -12.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-73.0% Q1'26: -23.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.8% ★ Q1'26: +12.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.3% Q1'26: +7.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.9% Q1'26: +2.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.0% Q1'26: +3.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.57× ★ Q1'26: 5.38× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|
| Revenue |
2.67B
est: 2.07B (+29.2%)
|
2.78B
est: 2.41B (+15.2%)
|
2.39B
est: 2.88B (-16.8%)
|
1.73B
est: 3.10B (-44.3%)
|
| EBITDA |
-180.33M
est: 245.41M (-173.5%)
|
473.81M
est: 286.61M (+65.3%)
|
533.12M
est: 327.54M (+62.8%)
|
246.22M
est: 353.28M (-30.3%)
|
| EBIT |
-321.11M
est: 83.64M (-483.9%)
|
329.84M
est: 97.68M (+237.7%)
|
336.05M
est: 81.58M (+311.9%)
|
39.78M
est: 87.99M (-54.8%)
|
| Net Income |
-359.98M
|
292.83M
|
279.84M
est: 392.61M (-28.7%)
|
77.00M
est: 452.09M (-83.0%)
|
| SGA |
1.20B
est: 768.07M (+56.4%)
|
1.36B
est: 897.00M (+51.9%)
|
803.31M
est: 1.09B (-26.1%)
|
385.07M
est: 1.17B (-67.2%)
|
| EPS |
-0.30
|
0.25
|
0.24
est: 0.33 (-27.3%)
|
0.06
est: 0.38 (-83.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 166.3K | 0.06% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 22.5K | 0.46% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 79.4K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 41.3K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.8K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 13.1K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 647.4K | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 38.8K | 0.28% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 544.3K | 0.05% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 55.8K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jing Feng | Deputy General Manager | — | female |
| Lu Wang | GM & Executive Director | — | male |
| Qin Tang | Secretary of the Board of Directors & Director | — | male |
| Tao Huang | Vice Chairman, Deputy GM & Director | — | male |
| Wei Wang | Deputy General Manager | — | male |
| Xiao Li Gan | Accounting Supervisor | — | — |
| Xue Song Yu | Deputy GM, Chief Financial Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300194.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
